Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocolSarah Nikiforow, Susan E. Prockop, Nancy Bunin et al.|Blood Advances|2024Cited by 23
Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.Jonathan W. Friedberg, Christopher A. Yasenchak, Andres Forero‐Torres et al.|Journal of Clinical Oncology|2018Cited by 4